Cipla Medpro is proud to announce that Dr. Yusuf Hamied, Cipla’s Chairman, has been elected an Honorary Fellow of the Royal Society, U.K. for his service to the cause of science. His election to this position is the culmination of a long career wherein he was instrumental in the growth of science in the indigenous pharma industry in India. The Royal Society commended Dr. Hamied specifically for his humanitarian approach in providing access to affordable healthcare.
Paul Miller, CEO of Cipla Medpro, said: “We applaud Dr Hamied on this notable lifetime award as the pinnacle of achievement in science. It is extremely well deserved for a career dedicated to the service of humanity, directly combatting the most threatening diseases and epidemics humans have ever encountered. His clear passion for expanding access to medicines has saved millions of people living in some of the most vulnerable populations in the world. As part of the Cipla team, we are incredibly proud of his contribution and achievement.”
Dr. Hamied graduated with honours from Cambridge University in 1957 and completed a PhD in 1960 under the tutelage of the Nobel Laureate Alexander Todd. During his career, Dr, Hamied commercially synthesised many essential drugs in diverse therapy areas including steroids, antibiotics, HIV/AIDS, respiratory and oncology drugs. Among some of his most significant achievements, was the ground-breaking syntheses of three anti-retroviral drugs, combined into a single dose therapy. This discovery made treatment for people living with HIV/AIDS more affordable (reducing the cost from $12000 annually to less than $1 a day in 2001). This humanitarian initiative has saved millions of lives in Africa alone.
The Royal Society is a fellowship of the world’s most eminent scientists and is the oldest scientific academy in continuous existence. A Fellowship from this institution is considered one of the highest honours in the scientific community and is only awarded to candidates who have made substantial lifetime contributions to their fields.
“I felt personally touched by Dr. Hamied’s point in his acceptance speech that the pharmaceutical industry requires the combination of both business acumen and humanitarian responsibility. This ethos resonates throughout Cipla globally, creating a thriving business driven by each individual’s inner humanity and desire to help those in need and particularly people suffering from diseases,” said Miller.
He added that Cipla is an organisation with a purpose, which is demonstrated every day through its ethos of “Caring for Life” and helping to make a difference in the life of a patient. As a business, Cipla is acutely aware of the responsibility it has to patients and it results in management with the appropriate sense of responsibility. “Dr. Hamied’s impact on science and medicine already far exceeds what can be expected from any one man, but we know that he will continue to innovate and inspire, shaping healthcare throughout the world,” Miller concluded.